[Top] [All Lists]

[e-lek] Fwd: [e-drug] Independent Drug and Healthcare Newsletter for November 2018

E-DRUG: Independent Drug and Healthcare Newsletter for November 2018

November 2018
Independent Drug & Healthcare Newsletter
from the non-profit journal Prescrire International

> View the contents
If your friends or colleagues would be interested, forward this email and
invite them to sign up for the free Newsletter.

Like what you see?
Subscribe to Prescrire International

In Prescrire's Spotlight this month

FEATURED REVIEW  Drug-induced gynaecomastia
Drug-related proliferation of male breast tissue generally subsides after
discontinuation of the substance that caused it. This must be weighed
against the potential disadvantages of stopping treatment or substituting
another drug.
> Read more

FREE DOWNLOAD  In the November issue of Prescrire International: Ending
pharmaceutical sales representatives' access to hospitals and students.
In-person promotion of drugs to healthcare professionals by pharmaceutical
sales representatives, known as pharmaceutical detailing, has been shown to
influence doctors' prescribing behaviour. A US study looked at ways to
limit this influence.
> Read more

SUBSCRIBE ONLINE  Subscribe today for instant access to top-quality content
from Prescrire International
Enjoy instant access to subscriber-only content available on our website,
including every article published in Prescrire International since 1992.
Prices for a one-year subscription start at 150 euros (less for students
and residents of lower-income countries).
>Subscribe now

Alcohol dependence: the risks of high-dose baclofen
With high-dose baclofen, there is an increased risk of epilepsy, infection,
myocardial infarction or suicidal thoughts.
> Read more

Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable
harm-benefit balance
Reports of sometimes serious adverse effects tilt the harm-benefit balance
of denosumab in the treatment of osteoporosis.
> Read more

Venetoclax (Venclyxto°): another drug made available on the market too soon
Ventoclax inhibits a protein often present in abnormal lymphocytes in cases
of chronic lymphocytic leukaemia. But does venetoclax extend the patient's
life span? We don't know because we don't have a comparative trial.
> Read more

Health technology assessment: the European Parliament's position improves
substantially upon the Commission proposal
The European Parliament (EP) has adopted by a large majority its position
on the proposed Regulation on health technology assessment (HTA). For
Prescrire, the EP's position improves the Commission proposal to a great
extent by outlining evaluation needs and improving transparency and
> Read more

COMING SOON  Enjoy these features, and more, in our upcoming issues
Nasal naloxone in opioid overdose * Valproic acid and pregnancy *
Fluoroquinolones and ACE inhibitors * Hormonal contraception and suicide *
Rivaroxaban and unstable angina * Omalizumab and severe asthma * Prices for
hepatitis C drugs * Healthcare-related errors...
>Subscribe now

Prescrire International <international@prescrire.org>
E-Drug, an e-forum on essential drugs, is moderated by a team of
international experts and hosted by FHI 360

To subscribe:  e-drug-join@healthnet.org
To unsubscribe:  e-drug-leave@healthnet.org
To discuss (subscribers only):  e-drug@healthnet.org
For help:  e-drug-owner@healthnet.org
For archives:  http://lists.healthnet.org/archive/html/e-drug/
<Prev in Thread] Current Thread [Next in Thread>
  • [e-lek] Fwd: [e-drug] Independent Drug and Healthcare Newsletter for November 2018, L-E Z <=